id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-E-4588-0006,FDA,FDA-2016-E-4588,Determination of Regulatory Review Period for Purposes of Patent Extension; XTAMPZA ER,Notice,Determinations,2024-12-30T05:00:00Z,2024,12,2024-12-30T05:00:00Z,2025-03-01T04:59:59Z,2025-02-24T02:00:23Z,2024-31023,0,0,0900006486894b77
FDA-2016-E-4588-0005,FDA,FDA-2016-E-4588,Letter to U.S. Patent and Trademark Office,Other,Assessment Document or Analysis,2024-12-19T05:00:00Z,2024,12,2024-12-19T05:00:00Z,,2024-12-19T13:29:15Z,,0,0,090000648687e052
FDA-2016-E-4588-0004,FDA,FDA-2016-E-4588,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-03-22T04:00:00Z,2024,3,2024-03-22T04:00:00Z,,2024-03-22T18:21:21Z,,0,0,090000648648d320